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Adenocarcinoma of the pancreas is one of the most common
causes of cancer deaths in the Western world. At the time of diag-
nosis, the vast majority of patients have advanced disease and the
tumour is no longer respectable. For many years, 5-fluorouracil
has been the standard chemotherapeutic drug used in the treatment
of pancreatic cancer, and more recently gemcitabine has shown
promising activity (Rothenberg et al, 1996) and is gaining wide-
spread use. However, response rates fail to exceed 20% even with
combination therapy (Evans et al, 1996; Dippold et al, 1997) and
neither radiation nor chemotherapy significantly improve long-
term survival (Gansauge et al, 1996; Rosewicz and Wiedenmann,
1997). The dismal prognosis of this disease makes it an appro-
priate model for evaluation of new, alternative therapies such as
treatment with differentiating agents like retinoids and vitamin D
analogues.
Retinoids, which are derivatives of vitamin A, are important
factors involved in the control of many biological functions,
including cell growth and differentiation, development and
carcinogenesis. The main function of the active metabolite of
vitamin D3, 1,25-dihydroxyvitamin D3 (1,25D3), is as a regulator
of serum calcium, although it also has effects on normal and
malignant tissue similar to those of the retinoids. Studies of the
anti-tumour actions of retinoids and vitamin D derivatives show
that growth inhibition, cellular differentiation and/or apoptosis can
be induced in a variety of cell types (Bollag et al, 1994; Lotan,
1996; Nagy et al, 1998). A major limitation to the use of 1,25D3 in
a therapeutic setting is its potent induction of hypercalcaemia, and
to circumvent this problem synthetic analogues with a more
favourable profile of activity have been developed. Two of several
that have been extensively characterized are EB1089 (Mathiasen
et al, 1993) and CB1093 (Danielsson et al, 1997) (Figure 1). They
both have more potent growth inhibitory effects than 1,25D3 and
EB1089 is also significantly less hypercalcaemic in vivo (Colston,
1997).
Most pancreatic cancer cells express the vitamin D receptor
(VDR) (Kawa et al, 1996; Colston et al, 1997) as well as receptors
for the retinoic acids (Rosewicz et al, 1995), suggesting that these
cells may respond to treatment with these agents.
The retinoids and 1,25D3 and its analogues exert most of their
effects by binding to specific receptors belonging to the nuclear
receptor superfamily. These receptors act as ligand-dependent
transcription factors, switching a variety of genes on and off
(Evans, 1988). There are two families of receptors binding the
retinoic acids: the retinoic acid receptors (RARs) and the retinoid
X receptors (RXRs). Each family has three subtypes, a, b and g,
and each of those a number of isoforms. This fact, together with
differential expression of the receptor subtypes in various tissues
and cell types, results in a board spectrum of biological activity
being affected by the retinoids in vivo.
The natural ligand for RARs is all-trans-retinoic acid (ATRA),
whereas the stereoisomer 9cRA binds to both RARs and RXRs
with high affinity (Giguere et al, 1987; Petkovich et al, 1987;
Heyman et al, 1992; Levin et al, 1992). RXRs also play a very
important role in heterodimerization with other nuclear receptors
such as VDR and RARs. All nuclear receptors bind as dimers to
specific cis-acting hormone response elements (HREs) on the
genes they control. VDR and RARs can bind to DNA as homod-
imers but for high affinity binding they require the presence of
RXRs. This forms the molecular basis for interactions between
retinoids binding to RXRs and vitamin D analogues (Kliewer et al,
1992; Haussler et al, 1995). In many cells the two groups of
compounds affect growth and differentiation in similar ways.
However, studies of the effects of 9cRA in combination with
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doi: 10.1054/ bjoc.2000.1281, available online at http://www.idealibrary.com on vitamin D compounds indicate that the story is more complex and
antagonistic as well as synergistic or additive effects can be seen in
different systems (discussed in Haussler et al, 1998).
In the present study, the inhibitory effects of ATRA, 9cRA and
the vitamin D analogues EB1089 and CB1093 on the three pancre-
atic adenocarcinoma cell lines AsPc-1, BxPc-3 and T3M-4 were
investigated. Our results demonstrate varying degrees of sensi-
tivity to all compounds, as evidenced by inhibition of in vitro
growth. However, we also show that the retinoids and the vitamin
D analogues employ different inhibitory mechanisms, as 9cRA but
neither EB1089 nor CB1093 induced apoptosis and the vitamin D
compounds even blocked apoptosis induced by 9cRA in the
pancreatic adenocarcinoma cells.
MATERIALS AND METHODS
Cell lines
Human pancreatic adenocarcinoma cell lines AsPc-1 (Chen et al,
1982), BxPc-3 (Tan et al, 1986) and T3M-4 (Okabe et al, 1983)
were obtained from Prof. N Lemoine (ICRF, London) and the
American Tissue Culture Collection. All cells were maintained in
RPMI-1640 culture medium with 10% fetal calf serum (FCS), 2
mML -glutamine and antibiotics at 37°C in a humidified atmos-
phere containing 5% carbon dioxide. For growth inhibition and
apoptosis studies cells were grown in medium containing 2.5%
FCS. All cells were routinely tested for mycoplasma contamination.
Compounds
ATRA and 9cRA were purchased from Sigma (Poole, UK).
EB1089 and CB1093 were provided by Leo Pharmaceutical
Products (Ballerup, Denmark). The compounds were dissolved in
ethanol and stored in the dark at –20°C. Dilutions were made up in
complete culture medium and the final ethanol concentration did
not exceed 0.1%. The maximal concentrations used were 500 nM
for 9cRA and 50 nM for EB 1089 and CB1093.
Growth inhibition assays
Total cell numbers were assessed using the aminoxanthene dye
sulphorhodamine B (SRB). SRB binds to basic amino acid
residues in the cells and gives an index of culture cell protein 
that is linear with cell number (Skehan et al, 1990). Cells were
plated in 48-well plates at a density of 2 ´ 103 cells per well. After
24–48 h normal culture medium was exchanged for medium
containing 2.5% serum and the inhibitory compounds. Control
cells received 0.1% ethanol and fresh medium was added every
2–3 days. At the end of each experiment cells were fixed in 10%
trichloroacetic acid (TCA) and stained with SRB. Bound SRB was
solubilized in unbuffered 10 mM Tris, 50 ml aliquots were trans-
ferred to 96-well plates and the optical density was measured at
550 nm.
Propidium iodide staining and cell cycle analysis
After treatment with 9cRA or EB1089 cells were harvested by
trypsinization, washed twice with sample buffer (PBS + 1 g l–1
glucose) and fixed in 70% ethanol at a density of 1 ´ 106 cells ml–1.
After > 18 h the cells were washed with sample buffer and
resuspended in propidium iodide (PI) staining solution containing
50 mg ml–1 PI and 20 mg ml–1 RNAase. Fluorescence was
measured on a Becton-Dickinson FACScan and DNA histograms
were analysed using ModFitLT software.
Apoptosis assays
The Boehringer-Mannheim Cell Death Detection ELISA kit,
which detects the presence of histone-associated DNA fragments
in the cell cytosol, was used according to the manual supplied by
the manufacturer. Results were confirmed using 7-AAD staining
followed by flow cytometry, as previously described (Philpott
et al, 1996) and PI staining as described above. The three methods
were compared and gave very similar results.
Statistical analysis
All statistical comparisons were made using an unpaired, two-
tailed t-test; *P < 0.05, ** P < 0.01, *** P <0.005.
RESULTS
Growth inhibition
AsPc-1, BxPc-3 and T3M-4 cells were treated with the test
compounds at the indicated concentrations for up to 6 days. Total
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Figure 1 Structures of 1,25-dihydroxyvitamin D3 and the analogues used in
the study
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Figure 2 All compounds tested induced inhibition of growth in AsPc-1,
BxPc-3 and T3M-4 cells. Total cell numbers were assessed on day 6 using
SRB staining and % inhibition was calculated compared to untreated control
cultures. Results are expressed as means ± standard deviations of three
separate experiments. Statistical comparisons were made of EB1089 vs
EB1089 + 9cRA and CB1093 vs CB1093 + 9cRAcell numbers were assessed using SRB staining. 9cRA, EB1089 as
well as CB1093 inhibited growth of the three pancreatic cell lines
in vitro, although AsPc-1 cells were less sensitive than BxPc-3 and
T3M-4. Reduction in cell numbers as compared to untreated
control cells was generally significant from day 4 (not shown). The
vitamin D compounds were more potent growth inhibitors than the
retinoic acids, with the maximal concentration of 50 nM resulting
in stronger inhibition than 50 or 500 nM of 9cRA. They were also
significantly more potent on their own than when combined with
9cRA. In two of the cell lines (BxPc-3 and AsPc-1) the combina-
tions were less efficient than any single-agent treatment, whereas
in T3M-4 cells the combinations were more efficient than 9cRA
on its own but less efficient than EB1089 and CB1093 (Figure 2).
Cell cycle analysis was performed on days 1, 2, 3 and 6 of the
treatment period for cells receiving 500 nM 9cRA, 50 nM EB1089
or a combination of the two. An increased proportion of cells in the
G0/G1 phase of the cell cycle was observed from day 2, but this
increase, together with a decrease in S phase, was statistically
significant only in cells receiving EB1089 alone (Figure 3). In
cells treated with 9cRA a population of cells containing less DNA
than cells in G1 could also be seen, indicating that the cells were
undergoing apoptosis (see below). In BxPc-3 cells, a sub-G1 peak
could be seen as early as day 2, whereas in AsPc-1 and T3M-4 this
change was only detectable on day 6.
Cells treated with the vitamin D analogues displayed character-
istic morphological changes. As previously described for butyrate-
induced differentiation in pancreatic tumour lines, cells became
enlarged and flattened with filamentous protrusions bridging sepa-
rate cells, indicating that the cells may be undergoing differentia-
tion (E1-Deriny et al, 1987) (Figure 4).
Induction of apoptosis
Following single-agent treatment with 9cRA, EB1089 or CB1093,
or co-treatment with 9cRA + EB1089 or 9cRA + CB1093 for 
6 days, apoptosis was assessed as described in Materials and
Methods. 9cRA alone was shown to induce apoptosis in all three
cell lines in a dose-dependent manner, whereas neither of the two
vitamin D analogues had this effect, even at the maximal concen-
tration of 50 nM (Figure 5). When EB1089 or CB1093 were added
to T3M-4 cells together with 9cRA a significant decrease in apop-
totic cell death could be seen (Figure 5B), indicating that the
vitamin D analogues blocked induction of apoptosis by 9cRA.
Similar effects were observed in cells co-treated with ATRA +
EB1089, such that EB1089 had a clearly negative effect on induc-
tion of apoptosis by ATRA (not shown).
T3M-4 cells were subsequently subjected to sequential treat-
ment with 50 nM of EB1089 for three days followed by 500 nM of
9cRA for 6 days. This resulted in complete blockage of apoptosis.
In contrast, pretreatment with 9cRA for three days before addition
of EB1089 did not make any difference compared to treatment
with EB1089 alone (Figure 5C).
Pretreatment with EB1089 for three days also resulted in
reduced apoptosis in response to the alkylating agent cisplatin 
(10 mM for 24 h), showing that the effect was not entirely specific
for retinoid-induced apoptosis (Figure 6).
DISCUSSION
The cell lines AsPc-1, BxPc-3 and T3M-4 are well-established in
vitro models of ductal pancreatic adenocarcinoma, representing
malignant cells derived from a primary tumour (BxPc-3), a lymph
node metastasis (T3M-4) and ascites (AsPc-1). In all three lines,
ATRA, 9cRA, EB1089 and CB1093 caused inhibition of cell
growth in vitro. Despite this, co-treatment with 9cRA and a
vitamin D analogue resulted in inhibition that was significantly
weaker than that induced by EB1089 or CB1093 alone. In two of
the cell lines the combinations were also less potent than 9cRA on
its own. This suggests that the retinoic acids and the vitamin D
compounds use different mechanisms to achieve the decrease in
cell number seen at the end of the treatment period.
While the retinoic acids were shown to induce apoptotic cell
death, EB1089 and CB1093 failed to do so. This is an interesting
observation as the cells do express VDR (Kawa et al, 1996 and
unpublished data) and are clearly responsive to the analogues,
which have been shown to induce apoptosis in various other 
cell types (James et al, 1995, 1998; Danielsson et al, 1997).
Furthermore, EB1089 and CB1093 not only failed to induce apop-
tosis by themselves, but were also able to completely block 
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Figure 3 Growth inhibition was accompanied by an accumulation of cells in
the G1 phase of the cell cycle, as determined by propidium iodide staining
and flow cytometric analysis. The concentrations used were 500 nM 9cRA
and 50 nM EB1089, alone or in combination. Percentages of cell in the
different cell cycle phases are shown for BxPc-3 and T3M-4 cells on day 2,
and are expressed as means of three determinationsinduction of apoptosis by 9cRA or ATRA. Again, this suggests
that the retinoic acids and the vitamin D compounds activate sepa-
rate mechanistic pathways and that those pathways are antago-
nistic and competitive.
The potential mechanisms underlying the antagonism seen
between 9cRA and the vitamin D analogues are numerous.
Clearly, in the case of co-treatment, direct receptor interactions
may play a role. In order to bind efficiently to their specific
hormone response elements VDR as well as RARs have to form
heterodimers with RXRs. RXRs on the other hand bind to DNA as
homodimers. This forms the basis for interactions and competition
between pathways activated by retinoids and vitamin D
compounds.
Pretreatment with EB1089 for 3 days was shown to be enough
to completely block induction of apoptosis by 9cRA. Hence, in
this period the vitamin D analogue provoke changes in the cell so
that it remains resistant to retinoid-induced apoptosis even after
the analogue is removed. Importantly, pretreatment with EB1089
also resulted in reduced apoptosis in response to the non-phase-
specific drug cisplatin, which indicates that the phenomenon is not
specific for apoptosis induced by retinoids, and accordingly effects
on RAR/RXR expression or receptor interactions cannot be solely
responsible. In agreement with this, assessment of receptor expres-
sion levels during different treatments showed no evidence of any
regulation that could be responsible for the observed antagonism
(not shown). It is therefore likely that regulation by vitamin D
analogues of genes whose products are involved in cell differenti-
ation, proliferation and death play the most important role in this
resistance. A number of genes are regulated by 1,25D3 and its
analogues, including the cyclin-dependent kinase inhibitors
(CDKI) p21WAF-1 and p27Kip1 (Liu et al, 1996; Wang et al, 1996;
Matsumoto et al, 1998). Both these proteins have been shown to
be up-regulated in the pancreatic cancer cell line BxPc-3 after
treatment with 1,25D3 as well as the synthetic analogue 22-oxa-
1,25-dihydroxyvitamin D3 (OCT) (Kawa et al, 1997), implying
that this is the mechanism whereby G0/G1 arrest is achieved.
p21WAF-1 can also protect cells from apoptosis in some systems
(Gartel and Tyner, 1999).
It has already been established that different cell types, and even
different cell lines of the same type, respond in different ways to
retinoids, vitamin D compounds and combinations of the two.
Additive and synergistic effects of the two groups of compounds
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Figure 4 T3M-4 cells photographed on day 6. Control cells (A) have just reached confluency whereas cells treated with 9cRA (B) show signs of dying and
cells treated with vitamin D analogues (C, D) are strongly growth inhibited and display morphological changesare commonly seen, e.g. in breast and prostate cancer cells where
both groups induce growth inhibition, G0/G1 arrest and apoptosis
(James et al, 1995; Elstner et al, 1999; Koshizuka et al, 1999).
Leukaemia cells on the other hand, show a different response
pattern. 9cRA as well as well as vitamin D induce differentiation,
and do so in a cooperative manner. Furthermore, it has been
observed in HL-60 cells that vitamin D derivatives, although
unable to induce apoptosis on their own, can potentiate induction
of apoptosis by 9cRA (James et al, 1999). Differential effects have
also been shown in melanoma and colon cancer cells (Kane et al,
1996; Danielsson et al, 1999).
In pancreatic cancer cells, responsiveness to both retinoids and
vitamin D analogues have been reported previously (Rosewicz et
al, 1995; Bold et al, 1996; Kawa et al, 1996; Louvet et al, 1996;
Zugmaier et al, 1996; Colston et al, 1997). However, those
studies have mainly assessed inhibition of cell growth and apop-
tosis has not been examined. In only one study were the
combined effects of retinoic acid and a vitamin D derivative
studied (Zugmaier et al, 1996), and in contrast to our results,
EB1089 potentiated the growth inhibitory effects of both ATRA
and 9cRA. The reason for this divergent effect, is most likely that
the cell lines studied (Capan-1 and -2) are at a different stage of
differentiation compared to our cell lines and distinct expression
patterns of RARs, RXRs and VDR may account for contrasting
responses. Capan-1 and -2 express lower levels of VDR than e.g.
BxPc-3 and are significantly less sensitive to 1,25D3 than this
cell line (Kawa et al, 1996). RAR-a and g are expressed in our
cell lines as well as Capan-1 and -2, but no or low levels of RAR-
b are generally detected (Rosewicz et al, 1995; Kaiser et al, 1998
and our observations).
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British Journal of Cancer (2000) 83(2), 239–245 © 2000 Cancer Research Campaign
Control
9cRA
EB1089
CB1093
BXPc-3 T3M-4 AsPC-1
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
E
n
r
i
c
h
m
e
n
t
 
f
a
c
t
o
r
E
n
r
i
c
h
m
e
n
t
 
f
a
c
t
o
r
E
n
r
i
c
h
m
e
n
t
 
f
a
c
t
o
r
A
2
4
6
8
1
2
3
4
5
C
o
n
t
r
o
l
C
o
n
t
r
o
l
B C
9
c
R
A
9
c
R
A
E
B
1
0
8
9
 
p
r
e
+
 
9
c
R
A
E
B
1
0
8
9
9
c
R
A
 
p
r
e
 
+
 
E
B
1
0
8
9
9
c
R
A
+
E
B
1
0
8
9
9
c
R
A
+
C
B
1
0
9
3
Figure 5 Assessment of apoptosis by Cell Death Detection ELISA, detecting the presence of histone-associated DNA fragments in the cell cytosol. The
enrichment factor is calculated as OD(treated cells)/OD(untreated cells). (A) 9cRA, but neither EB1089 nor CB1093 induced apoptosis in the three cell lines.
(B) Combinations of 9cRA with EB1089 or CB1089 resulted in very weak induction of apoptosis in T3M-4 cells compared to treatment with 9cRA alone,
and (C) preincubation with EB1089 for 3 days completely blocked induction of apoptosis by 9cRA. The concentrations used were 500 nM of 9cRA and 50 nM of
the vitamin D analogues. Statistical comparisons were made of control vs treated cells (A) and 9cRA vs 9cRA + EB1089 or CB1093 (B)The Bcl-2 family of proteins regulates responses to a variety of
apoptotic stimuli, and includes anti-apoptotic (Bcl-2, Bcl-XL, Mcl-
1 and A1) as well as pro-apoptotic members (Bax, Bcl-Xs etc.)
(Korsmeyer, 1999). For example, in breast cancer cells which
undergo apoptosis in response to vitamin D compounds, down-
regulation of the anti-apoptotic protein Bcl-2 and an increased
Bax/Bcl-2 ratio can be observed (James et al, 1998). This is also
observed in HL-60 leukaemia cells, and is thought to be a mecha-
nism whereby vitamin D derivatives potentiate induction of apop-
tosis by 9cRA (James et al, 1999). However, 1,25D3 has also been
reported to have an anti-apoptotic effect in HL-60 cells, and this
was associated with induction of differentiation and up-regulation
of Mcl-1 (Wang and Studzinski, 1997). We are currently investi-
gating the effects of EB1089, CB1093 and 9cRA on expression of
these pro- and anti-apoptotic proteins in pancreatic cancer cells, to
assess their role in the differential effects observed.
The conclusions that can be drawn from this study are that both
retinoids and vitamin D analogues may have a role to play in
management of pancreatic cancer, but the outcome of the two
treatments will be different. Vitamin D analogues can slow down
cell growth but do not kill the cells, whereas retinoids do both. It
also points out that the two groups of compounds should probably
not be used together as they counteract each other in vitro.
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